- |||||||||| Invanz (ertapenem) / Merck (MSD), levofloxacin / Generic mfg.
Journal: Vibrio Albensis Bacteraemia in a Decompensated Cirrhotic Patient with an Atypical Transmission Source. (Pubmed Central) - Apr 16, 2026
Vibrio albensis is an extremely rare pathogenic organism in humans, with only 5 previously reported cases worldwide.Liver cirrhosis is a significant risk factor for invasive Vibrio albensis infection due to compromised immune function.Hospital-acquired infection with an unknown source suggests alternative transmission routes that warrant further investigation.
- |||||||||| FDA event, Journal: A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S-mutant NSCLC. (Pubmed Central) - Apr 16, 2026
These findings suggest that ertapenem and oxymetholone are promising structurally unique scaffolds for targeting osimertinib-resistant EGFR C797S-driven NSCLC. While experimental validation is necessary, this study provides a computational framework for swift drug repurposing and lays a rational foundation for future biochemical evaluation and structure-guided optimization of next-generation EGFR inhibitors.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), cisplatin / Generic mfg., pemetrexed / Generic mfg.
Journal, Checkpoint inhibition: Autoimmune Encephalitis Associated with Anti-titin Antibodies following Immune Checkpoint Inhibitor Therapy: A Case Report. (Pubmed Central) - Apr 16, 2026
This is the first documented case of anti-titin antibody-positive encephalitis in a patient with non-small cell lung cancer (NSCLC). This case highlights the importance of considering immune-mediated neurological complications during Immune Checkpoint Inhibitor (ICI) treatment and the value of early antibody detection and prompt immunosuppressive therapy.
- |||||||||| Remicade (infliximab) / J&J
Journal: Transverse myelitis as an initial presentation of sarcoidosis. (Pubmed Central) - Apr 16, 2026
Follow-up demonstrated radiological improvement and functional gains, though mild deficits persisted. This case highlights the importance of rapidly distinguishing between compressive and non-compressive spinal cord syndromes, the need for systematic investigation of inflammatory myelopathies, and the role of multidisciplinary management in neurosarcoidosis.
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Review, Journal, BRCA Biomarker, PARP Biomarker: The complex landscape of non-coding RNAs in olaparib response and resistance. (Pubmed Central) - Apr 16, 2026
Subsequently, we explore how olaparib treatment itself can alter the expression profile of ncRNAs, creating a dynamic feedback loop that may influence therapeutic outcome. By consolidating these findings across various cancers, including ovarian, breast, prostate, and hepatocellular carcinoma, this review highlights the potential of ncRNAs as both predictive biomarkers and therapeutic targets to overcome PARPi resistance and enhance patient outcomes.
- |||||||||| olopatadine / Generic mfg., Ryaltris (olopatadine/mometasone) / Glenmark, mometasone furoate nasal spray / Generic mfg.
Retrospective data, Journal: Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials. (Pubmed Central) - Apr 16, 2026
P2, P3
Moreover, this study showed that Olo/Mom has a rapid onset of action and significantly improves RQLQ scores compared to placebo. Administration of Olo/Mom BID is an effective and well-tolerated option for the treatment of SAR in patients aged 12-years or older.
- |||||||||| anzutresgene autoleucel (IMA203) / Immatics
New P3 trial: SUPRAME-ACTengine (clinicaltrials.gov) - Apr 15, 2026
P3, N=96, Recruiting,
- |||||||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: QUILT2023: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 15, 2026
P3, N=102, Terminated,
N=1538 --> 102 | Trial completion date: Dec 2026 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Oct 2025; There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.
- |||||||||| Remicade (infliximab) / J&J
Journal: Deterministic Acceptance Limits for Statistical Equivalence Testing in Hydrogen/Deuterium Exchange Mass Spectrometry. (Pubmed Central) - Apr 15, 2026
Therefore, we evaluated three strategies: robust outlier detection, a percentile-based method, and a partitioning approach to establish more stringent criteria and reduce patient risk. By applying the enhanced methods to data sets of three approved infliximab biosimilars and a partially deglycosylated NIST mAb used as a mock candidate biosimilar, we demonstrated correct classification of equivalent and nonequivalent samples, making the enhanced evaluation strategy well suited for regulatory comparability assessment.
- |||||||||| Retrospective data, Journal: Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma. (Pubmed Central) - Apr 15, 2026
Systemic standard of care treatments for mRCC, which include vascular endothelial growth factor receptor targeted therapy (VEGF-TT [sunitinib or pazopanib]), immune-oncology-VEGF (IO-VE [pembrolizumab and axitinib, pembrolizumab and lenvatinib, nivolumab and cabozantinib, or avelumab and axitinib]), and 2 IO (IO-IO [ipilimumab and nivolumab]) regimens...In this cohort study, the very favorable risk subgroup had a less immunogenic molecular profile and superior outcomes from VEGF-containing regimens (VEGF-TT and IO-VE) compared with the favorable risk group. The IO-IO combination showed significantly worse survival in this population, suggesting that VEGF inhibition remains essential for optimal outcomes.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / BMS
Journal, Microsatellite instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, MSI-H: Immunotherapy Response in Microsatellite Instability-High Gastroesophageal Adenocarcinoma. (Pubmed Central) - Apr 15, 2026
The durable responses in locoregional disease suggest the potential to consider nonoperative management in selected individuals. Further research is needed to improve prediction of ICI response and refine treatment strategies.
- |||||||||| raltegravir / Generic mfg.
Journal: Evolution and emergence of the integrase inhibitor 231 insertion resistance mutation in an HIV-2 strain isolated in central Portugal. (Pubmed Central) - Apr 15, 2026
This study reports the emergence of the IN codon 231 insertion resistance mutation in an HIV-2 strain isolated from a person with HIV-2 (PWH-2) undergoing antiretroviral treatment with a raltegravir (RAL) containing regimen, in central Portugal...The insertion profile found, GYRGK, was similar to those previously described, and clearly emerged under the selective pressure of RAL, which is in agreement with previously reported evidence of a significant correlation between treatment failure to INSTIs and the emergence of R231_insert containing viruses. Our findings expand the available genotypic data regarding this resistance pathway and should help to improve HIV-2 resistance interpretation algorithms.
- |||||||||| Journal: Bridging clinical and environmental reservoirs: antimicrobial resistance in the emerging pathogen Shewanella algae. (Pubmed Central) - Apr 15, 2026
Carbapenems displayed an unusual intraclass pattern, with imipenem showing markedly higher MICs than meropenem and ertapenem...Furthermore, plasmids harboring class 1 integrons (mobile integrons) were widespread, shared with Enterobacterales and Vibrionaceae across clinical and environmental settings. Overall, these findings highlight S. algae as both a clinically relevant pathogen and a reservoir of mobile AMR determinants and underscore the urgent need for species-specific antimicrobial susceptibility interpretive criteria to improve clinical decision-making for this emerging pathogen.
- |||||||||| dizocilpine (MK801) / Merck (MSD)
Preclinical, Journal: The effects and mechanisms of baicalin on MK-801 induced schizophrenia model (Pubmed Central) - Apr 15, 2026
ratios.ConclusionBaicalin may improve cognitive impairments in MK801-induced schizophrenia model mice through the PI3K/Akt/GSK3? signaling pathway, exhibiting anti-neuroinflammatory and neuroprotective effects.
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Lenvima (lenvatinib) / Eisai, Merck (MSD), sunitinib / Generic mfg.
Review, Journal: Case report: Renal clear cell carcinoma presenting with metastatic nodules in the male breast: a case and literature review. (Pubmed Central) - Apr 15, 2026
After two subsequent excisions of the breast metastases, the patient was treated with lenvatinib in combination with tislelizumab...The patient is currently maintained on sunitinib monotherapy...Our analysis underscores the need for thorough evaluation of breast nodules in patients with an RCC history, even absent classic signs like nipple retraction or discharge. These findings may contribute to the future development of effective management guidelines for breast metastases from RCC and help clinicians better recognize this clinical entity.
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Retrospective data, Journal, Real-world evidence, BRCA Biomarker, PARP Biomarker: BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study. (Pubmed Central) - Apr 15, 2026
In this real-world retrospective cohort, BRCA mutation status was associated with increased risk of clinically significant olaparib-related toxicity. These findings suggest that BRCA mutation status may help identify patients at higher risk of adverse events and support closer toxicity monitoring and individualized dose management during maintenance therapy.
- |||||||||| Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Update on pleural mesothelioma. (Pubmed Central) - Apr 15, 2026
Future research should prioritize mesothelioma-specific trials to define the role and sequencing of perioperative immunotherapy and novel agents. AI tools may assist disease diagnosis, prognostication, and treatment selection.
- |||||||||| Synacthen Depot (cosyntropin) / Mallinckrodt, Pharmanovia, Keytruda (pembrolizumab) / Merck (MSD), hydrocortisone / Generic mfg.
Journal: Delayed-onset central adrenal insufficiency following adjuvant pembrolizumab therapy for renal cell carcinoma. (Pubmed Central) - Apr 15, 2026
The patient improved rapidly after starting hydrocortisone replacement. This case highlights a prolonged interval between checkpoint inhibitor cessation and endocrine toxicity, emphasising the importance of continued surveillance for late-onset immune-related endocrinopathies even after therapy completion.
- |||||||||| Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
Journal: Unexpected Death in a Young Child With Cogan Syndrome. (Pubmed Central) - Apr 15, 2026
Treatment was then switched to tocilizumab, which led to both clinical and laboratory improvement...Unfortunately, there are no international guidelines for the treatment and follow-up of pediatric patients with CS. This case represents an uncommon manifestation of CS in a child and highlights the urgent need for evidence-based guidelines for the diagnosis, management, and long-term monitoring of these patients.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Finding Clarity in the Battle With Crohn's Disease. (Pubmed Central) - Apr 15, 2026
Nevertheless, a groundbreaking study in the U.K. by researchers at Cambridge University and NHS Trusts suggests that going for the stronger treatments early post-diagnosis might better control inflammation and, in the long run, be more cost-effective and yield better patient outcomes. Jim Banks investigates the pros and cons of changing the therapeutic pathway for a condition that keeps creating one conundrum after another.
- |||||||||| Lutathera (lutetium Lu 177 dotatate) / Novartis, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion: LuPARP: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (clinicaltrials.gov) - Apr 15, 2026
P1, N=18, Completed,
Jim Banks investigates the pros and cons of changing the therapeutic pathway for a condition that keeps creating one conundrum after another. Active, not recruiting --> Completed
- |||||||||| Capvaxive (V116) / Merck (MSD)
EVALUATING THE POTENTIAL HEALTH AND ECONOMIC IMPACT OF DIFFERENT STRATEGIES WITH V116 USE AMONG ADULTS IN JAPAN (Exhibition; Board-521) - Apr 14, 2026 - Abstract #ISPPD2026ISPPD_1013;
If one additional V116 vaccination were given either 5, 10, or 15 years later, the number of IPD cases would reduce to 863, 842, or 847, respectively, and NBPP deaths would reduce to 4,346, 4,288, and 4,259, respectively (Table 3).Conclusions V116 would prevent more health outcomes and reduce more treatment costs than PCV20 for both younger and older adults. Following PCV vaccination at age 65, the optimal timing for a single revaccination was found to be around 10-15 years.
- |||||||||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
VACCINE EFFECTIVENESS OF PCV15 AMONGST SWEDISH CHILDREN (Exhibition; Board-369) - Apr 14, 2026 - Abstract #ISPPD2026ISPPD_905;
The 10 valent pneumococcal conjugate vaccine (PCV10) was replaced by PCV15 (which includes additional serotypes 3, 6A, 19A, 22F and 33F) in the Swedish child immunization program in 2023...This study also aims to study the VE of PCV15 on all-cause acute otitis media (AOM) and the impact of the PCV15 vaccination program.Methods This population-based, longitudinal observational study in Sweden includes children under 5 years of age, using national and regional registers to collect data from 2015 to December 2027. Main health outcomes include IPD and all-cause AOM.Results Results are expected by 2028.Conclusions To our knowledge this is the first study evaluating the effectiveness and impact of PCV15 in children.
|
